Jane Street
CADL icon

Jane Street’s Candel Therapeutics CADL Stock Holding History

Jane Street’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,900
Closed -$192K – 9712
2025
Q1 		$192K Buy
+33,900
New +$277K ﹤0.01% 8485
2024
Q4 		– Sell
-40,000
Closed -$277K – 9456
2024
Q3 		$277K Hold
40,000
– – ﹤0.01% 8159
2024
Q2 		$248K Buy
+40,000
New +$300K ﹤0.01% 8097

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street's CADL Position: Q1 2026 in Review

Jane Street sold out of Candel Therapeutics (CADL) in Q1 2026, closing a stake of 10,799 shares — an estimated $58.8K sold.

Jane Street first reported a position in CADL in Q4 2022 and held it in 5 quarters. The position peaked at $227K in Q3 2024. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Jane Street reported no remaining Candel Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 10,799 Candel Therapeutics shares in Q1 2026, an estimated $58.8K.
  • Jane Street first reported a position in Candel Therapeutics in Q4 2022 and held it in 5 quarters.
  • Jane Street's Candel Therapeutics position peaked at $227K in Q3 2024.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.